DCI administration decreased FBS, improved glucose intolerance through PI3K/AKT pathway, namely by upregulating insulin receptor substrate (IRS) and PI3Kp85 as well as IRS‐2 and AKT phosphorylation (Cheng et al., 2019). This evidence concerns the gene IARS1 and Glucose intolerance.